Oseltamivir - Instructions For The Use Of An Antiviral Agent, Price

2024 Author: Rachel Wainwright | [email protected]. Last modified: 2023-12-15 07:39

Oseltamivir

Oseltamivir: instructions for use and reviews

1. 1. Release form and composition
2. 2. Pharmacological properties
3. 3. Indications for use
4. 4. Contraindications
5. 5. Method of application and dosage
6. 6. Side effects
7. 7. Overdose
8. 8. Special instructions
9. 9. Application during pregnancy and lactation
10. 10. Use in childhood
11. 11. In case of impaired renal function
12. 12. For violations of liver function
13. 13. Use in the elderly
14. 14. Drug interactions
15. 15. Analogs
16. 16. Terms and conditions of storage
17. 17. Terms of dispensing from pharmacies
18. 18. Reviews
19. 19. Price in pharmacies

Latin name: Oseltamivir

ATX code: J05AH02

Active ingredient: oseltamivir (Oseltamivir)

Manufacturer: Izvarino Pharma, LLC (Russia); Ozon Pharm, OOO (Russia)

Description and photo update: 2019-23-10

Prices in pharmacies: from 652 rubles.

Buy

Oseltamivir is an oral antiviral agent.

Release form and composition

The drug is produced in the form of capsules: hard gelatinous, opaque; depending on the manufacturer - size No. 4 (dosage 30 mg), No. 3 (dosage 45 mg) and No. 1 (dosage 75 mg), body and lid - from almost white or white to white with a yellow tint; the contents of the capsules are a compacted powder mass or powder from almost white or white to white with a yellow tinge; either size No. 2 (dosage 30 and 45 mg), body and cap - yellow (dosage 30 mg) or dark gray (dosage 45 mg), or No. 0 (dosage 75 mg), body pale gray and yellow cap; the contents of the capsules are a mixture of granules and powder of white or white with a yellow tinge color with possible compaction into capsule-shaped lumps, easily crumbling when pressed (depending on the manufacturer: 5, 7, 10, 14 or 15 pieces in a blister strip,in a cardboard box 1, 6 or 9 packs of 10 pcs., or 1, 2, 4 or 6 packs of 15 pcs., or 1, 2, 3, 4, 5 or 10 packs of 5, 7, 10 or 14 pcs..; 10, 20, 30, 40, 50 or 100 pcs. in a jar made of polyethylene terephthalate, in a cardboard box 1 jar. Each pack also contains instructions for the use of Oseltamivir).

Composition for 1 capsule:

• active substance: oseltamivir phosphate - 39.41; 59.12 or 98.53 mg, which is equivalent to oseltamivir in the amount of 30, 45 and 75 mg, respectively;
• additional components (depending on the manufacturer): pregelatinized corn starch, povidone K25 or K30, corn starch, croscarmellose sodium, sodium stearyl fumarate, talc;
• capsule shell: titanium dioxide, gelatin; additionally, depending on the manufacturer - quinoline yellow dye and sunset yellow dye (No. 2 dosage 30 mg and No. 0 dosage 75 mg), iron oxide black oxide dye (No. 2 dosage 45 mg and No. 0 dosage 75 mg).

Pharmacological properties

Pharmacodynamics

Oseltamivir is a prodrug, its active metabolite, oseltamivir carboxylate (OC), is an effective and selective inhibitor of neuraminidase of influenza A and B viruses. Neuraminidase is an enzyme that catalyzes the process of release of produced viral particles from infected cells, their subsequent entry into uninfected epithelial cells ways and further distribution in the body. The agent blocks the growth of the influenza virus in vitro and inhibits the replication of the virus, as well as its pathogenicity in vivo, reducing the release of influenza A and B viruses into the environment from the body. OC content required to suppress 50% of neuraminidase (IC ₅₀, or the concentration of half-maximum inhibition), is: for influenza A virus - 0.1-1.3 nM, for influenza B virus - 2.6 nM. The median IC ₅₀ values are slightly higher for influenza B virus at 8.5 nM.

In the course of the studies conducted, oseltamivir did not show any effect on the production of anti-influenza antibodies, including the formation of antibodies in response to the administration of an inactivated influenza vaccine.

Participants in clinical trials conducted during the period of seasonal influenza infection began to receive oseltamivir no later than 40 hours after the first signs of the disease appeared. 97% of patients were infected with influenza A virus and 3% with influenza B virus. The drug reduced the time of manifestations of influenza infection by 32 hours. In oseltamivir-treated patients with a confirmed diagnosis of influenza, the severity of the disease, expressed as area under the curve for the cumulative symptom index, was 38% lower when compared with patients taking placebo. In young people who did not have concomitant diseases, the drug provided a decrease in the incidence of complications of influenza (sinusitis, otitis media, bronchitis, pneumonia) requiring antibiotic prescription by an average of 50%. Was found,that the drug also led to a shortening of the period of virus isolation from the body and a decrease in the area under the viral titers-time curve.

When treating elderly and senile patients with the drug, according to the data obtained, taking the drug at a dose of 75 mg 2 times a day for 5 days was accompanied by a clinically significant decrease in the median time of manifestations of influenza infection, corresponding to that in younger patients, but there were no differences. had statistical significance.

Against the background of another study, persons over 13 years old, patients with influenza, with concomitant chronic lesions of the cardiovascular and / or respiratory systems, took oseltamivir in the same dosing regimen or placebo. There were no differences in the median of the period before the reduction of influenza symptoms in the oseltamivir and placebo groups, however, the period of fever with the use of the drug was reduced by about 1 day, and the number of patients shedding the virus on days 2 and 4 decreased significantly.

A double-blind, placebo-controlled study was conducted for the treatment of influenza in children 1–12 years of age with a body temperature above 37.8 ° C and with cough or rhinitis during the circulation season. 67% of patients were infected with influenza A virus and 33% with influenza B. In the case of using Oseltamivir, no later than 48 hours after the onset of the first signs of infection, the duration of the disease, defined as the time until the symptoms of the lesion subsided and return to normal activity, compared with placebo, decreased by almost 2 days (by 35.8 hours). In the group of children taking the drug, the incidence of acute otitis media decreased by 40%.

In another study, in children 6–12 years old with bronchial asthma, treatment of influenza with oseltamivir did not significantly reduce the median duration of the disease. However, by the last, sixth, day of taking the drug, the forced expiratory volume in 1 second (OFB ₁) increased by 10.8% compared to 4.7% in children who received placebo.

The efficacy of Oseltamivir for the prevention of influenza in adults and adolescents with natural influenza infection has been established in 3 separate phase III studies. During the period of taking the drug, about 1% of patients fell ill with influenza, the frequency of virus shedding was also significantly reduced and the transmission of the virus from one family member to another was prevented. In patients who had contact with a sick family member who started taking the drug within 2 days of the onset of flu symptoms in family members and continued taking it for 7 days, the incidence of influenza decreased by 92%.

In unvaccinated and generally healthy individuals aged 18–65 years, the use of oseltamivir for 42 days during the influenza epidemic contributed to a 76% decrease in the incidence.

In elderly and senile patients staying in nursing homes (the number of those vaccinated before the infection season was 80%), the drug reduced the incidence of influenza by 92%, while the frequency of influenza complications in the form of sinusitis, bronchitis and pneumonia decreased by 86%. The preventive course was 42 days.

The prophylactic effect of the drug was studied in children 1–12 years old who received oseltamivir phosphate in powder form for the preparation of a suspension for oral administration in a dose of 30–75 mg once a day for 10 days. In children who had contact with a sick family member with natural influenza infection, the incidence of laboratory-confirmed influenza decreased to 4% compared to 21% in the placebo group.

In the presence of weakened immunity against the background of seasonal influenza infection, prophylactic administration of the drug led to a decrease in the incidence of influenza with clinical symptoms to 0.4% compared to 3% in the placebo group.

In clinical studies of drug resistance in all carriers of the OK-resistant virus, the carriage was transient, did not affect the elimination of the virus and did not lead to a worsening of the clinical condition. During the period of use of oseltamivir for seasonal prophylaxis (42 days), post-exposure prophylaxis (7 days) and during contacts with the patient in the family (10 days) in the absence of impaired immune system function, no cases of drug resistance were recorded.

Naturally occurring mutations of influenza A and B viruses were identified in individuals not taking oseltamivir, which had reduced sensitivity to the drug. The H275Y substitution mutation causing resistance has been identified in more than 99% of the 2008 H1N1 virus strains circulating in Europe. In most cases, the causative agent of 2009 H1N1 influenza (swine flu) was susceptible to oseltamivir. Drug-resistant strains have been identified in individuals with normal and weakened immune system function who received the drug. The incidence of these viruses and the degree of reduction in susceptibility to oseltamivir may vary by region and season. Resistance to the drug was found in patients with pandemic H1N1 influenza who used the drug for both therapy and prophylaxis.

The detection rate for resistance may be higher in younger patients and immunocompromised individuals. Oseltamivir-resistant laboratory strains of influenza viruses and influenza pathogens from patients treated with the drug carry N1 and N2 neuraminidase enzyme mutations. Resistance-inducing mutations are often subtype-specific for neuraminidase.

Deciding whether to use oseltamivir requires considering the seasonal sensitivity of the virus to the drug (see the WHO website for the latest information).

Pharmacokinetics

The active substance of the drug is easily absorbed in the gastrointestinal tract (GIT) under the action of intestinal and hepatic esterases and is extensively converted into an active metabolite (OC). Plasma levels of TC are determined within 30 minutes and are more than 20 times higher than the concentration of the prodrug. The period of reaching the maximum concentration (C _max) of OC is 2–3 hours. At least 75% of the orally administered dose in the form of an active metabolite and less than 5% in the form of oseltamivir phosphate enters the systemic circulation.

Plasma concentrations of both the parent drug and OC are dose proportional and do not depend on food intake. The volume of distribution in the equilibrium state (V _ss) is 23 liters (for OC).

According to the results of preclinical studies in animals, after oral administration of the drug, its active metabolite in concentrations providing an antiviral effect was detected in all major foci of infection - the nasal mucosa, middle ear, trachea, bronchial and lung washings.

Communication with plasma proteins OK - 3%, and prodrugs - 42%, which is not enough for significant drug interactions.

Oseltamivir phosphate is transformed into an active metabolite with the participation of esterases, mainly in the liver. Neither the starting agent nor TC are inhibitors or substrates of isozymes of the cytochrome P _{450 system}.

More than 90% of the drug in the form of an active metabolite is excreted mainly by the kidneys. OA does not undergo further transformation and is almost completely (> 99%) eliminated by the kidneys through glomerular filtration and tubular secretion. The glomerular filtration rate is 7.5 l / h, and the renal clearance is 18.8 l / h, which indicates that the drug is also excreted by tubular secretion. The half-life (T _1/2) of the active metabolite is 6-10 hours. Less than 20% of the drug taken orally is excreted in the feces.

According to pharmacokinetic studies in children aged 1 to 16 years, the rate of elimination of oseltamivir carboxylate, adjusted for body weight, was higher in young children than in adults, which provided lower values of the area under the concentration-time curve (AUC) of the substance in relation to a specific dose.

The use of the drug at a dose of 2 mg / kg or the administration of single doses of 30 or 45 mg in accordance with the recommendations for dosing in children specified in the section "Method of administration and dosage" leads to a similar AUC OC value recorded in adults after a single use of a 75 mg capsule (which is equivalent to an average of 1 mg / kg). In adolescents over 12 years of age, the pharmacokinetic parameters of the antiviral agent are the same as in adults.

In patients with varying degrees of renal dysfunction, when using the drug for 5 days at a dose of 100 mg 2 times a day, the AUC value of the active metabolite is inversely proportional to the decrease in renal function. In persons with end-stage renal failure (with a CC value of 10 ml / min and below) who are not undergoing dialysis, the pharmacokinetics of oseltamivir have not been studied, therefore, the drug is contraindicated in patients from this risk group.

According to the results of preclinical and clinical studies, a significant increase in the AUC of oseltamivir was not detected in mild / moderate hepatic impairment. In patients with severe hepatic impairment, the pharmacokinetics and safety of the drug have not been studied.

In patients aged 65–78 years, the AUC of the active metabolite of the drug in the equilibrium state was 25–35% higher than in younger people when using similar doses of oseltamivir. In elderly patients, the T1 _{/ 2} values of the drug did not differ significantly from those in young adult patients.

Indications for use

• treatment of influenza in children over 1 year old, adolescents and adults;
• prevention of influenza in children over 1 year old;
• prevention of influenza in adolescents over 12 years old and adults who are at increased risk of infection with the virus (including in debilitated patients, in large production teams and military units).

Contraindications

Absolute:

• age up to 1 year;
• renal failure in the terminal stage [with creatinine clearance (CC) 10 ml / min and below];
• severe liver failure;
• hypersensitivity to any of the constituents of the drug.

Oseltamivir should be taken with extreme caution during pregnancy and lactation.

Oseltamivir, instructions for use: method and dosage

Oseltamivir capsules are taken orally, with or without food (taking the antiviral agent with food can improve tolerance).

If a patient of any age has trouble swallowing a whole capsule, one or more capsules required for 1 dose can be opened and the contents are carefully poured into a small container, and then diluted in a small amount (no more than 1 teaspoon) of a suitable sweetened product to hide bitter taste. For these purposes, honey, table or light brown sugar dissolved in water, condensed milk with sugar, sweet dessert, yogurt or applesauce, chocolate syrup with or without sugar may be suitable. The resulting mixture must be carefully moved and then consumed whole. The suspension must be taken immediately after preparation. If a little of the mixture remains in the container, then the latter should be rinsed with a small amount of water and the rest of the product should be drunk. This procedure must be performed before each dose of Oseltamivir. Before preparing the suspension, you must ensure that the correct dose is used, in accordance with the recommendations below.

Therapy

It is required to start taking Oseltamivir no later than 2 days after the onset of symptoms of infection, the course of treatment is 5 days.

The recommended single doses of the drug, depending on the patient's age, the frequency of administration - 2 times a day:

• children from 8 years and older or with a body weight of more than 40 kg (if there are no difficulties with swallowing a capsule), adolescents and adults: 75 mg each (1 capsule 75 mg or 1 capsule 30 mg + 1 capsule 45 mg); increasing the daily dose of more than 150 mg does not enhance the effect;
• children from 1 to 8 years old: capsules of 30 and 45 mg or a suspension prepared extemporally should be used: with a weight of more than 40 kg - 75 mg; from 23 to 40 kg - 60 mg; from 15 to 23 kg - 45 mg; 15 kg or less - 30 mg.

Prevention

It is required to start taking Oseltamivir no later than 2 days after contact with the patient.

Recommended dosage regimen:

• adolescents from 12 years old and adults: 1 time per day, 75 mg (1 capsule 75 mg or 1 capsule 30 mg + 1 capsule 45 mg) for 10 days after contact with the patient; during a seasonal flu epidemic - 75 mg once a day for 42 days; the preventive effect is observed during the entire period of taking the drug;
• children from 8 to 12 years old or with a body weight of more than 40 kg (in the absence of problems with swallowing a capsule): once a day, 75 mg (1 capsule 75 mg or 1 capsule 30 mg + 1 capsule 45 mg), course - 10 days;
• children from 1 to 8 years old: use capsules of 30 and 45 mg or an extemporaneously prepared suspension; with a weight of more than 40 kg - 75 mg; from 23 to 40 kg - 60 mg; from 15 to 23 kg - 45 mg; 15 kg or less - 30 mg; depending on the manufacturer - the frequency of admission is 2 times a day for 5 days or 1 time a day for 10 days.

In immunocompromised individuals over the age of 1 year, Oseltamivir is recommended to be taken for seasonal prophylaxis of influenza for 12 weeks, no dose change is required

Side effects

In the course of studies on the treatment and prevention of influenza in adolescents and adults, the most frequently observed undesirable effects of the drug were headache, nausea, vomiting, additionally for prevention - pain (the difference with placebo was ≥ 1%). As a rule, these disorders during therapy developed on the first / second day of the course and disappeared on their own within 2 days. Vomiting was most frequently observed in children. In most cases, these reactions did not require discontinuation of Oseltamivir.

Side effects recorded during studies in adolescents and adults with a frequency of ≥ 1% when using the drug for the prevention and treatment of influenza infection:

• Gastrointestinal tract: treatment - abdominal pain, diarrhea; prevention - dyspepsia, pain in the upper abdomen, diarrhea;
• infections and invasions: treatment - sinusitis, herpes simplex, bronchitis; prevention - upper respiratory tract infections, nasopharyngitis, influenza infection;
• respiratory system, chest and mediastinal organs: treatment - nasal congestion, cough; prevention - nasal congestion, rhinorrhea, cough, tonsillitis;
• nervous system: treatment / prevention - insomnia;
• genitals and mammary gland: prevention - dysmenorrhea;
• musculoskeletal and connective tissue: prevention - myalgia, arthralgia, back pain;
• general disorders: treatment - dizziness, including vertigo; prevention - pyrexia, fatigue, dizziness, flu-like illness, pain in the limb.

In older patients, the safety profile did not differ clinically from that of younger patients with treatment / prevention of influenza. In immunocompromised individuals, the safety profile was similar to that described in studies of a drug for the prevention of influenza.

Adverse effects observed in studies of the use of oseltamivir in children, with a frequency of ≥ 1% in the treatment of influenza (n = 858) or with a frequency of ≥ 5% in the prevention of influenza infection (n = 148):

• Gastrointestinal tract: treatment - nausea, abdominal pain (including pain in its upper part), diarrhea;
• respiratory system, chest and mediastinal organs: treatment - epistaxis, asthma (including the period of exacerbation); prevention - nasal congestion, cough;
• infections and invasions: treatment - sinusitis, otitis media, bronchitis, pneumonia;
• the organ of hearing and labyrinth disorders: treatment - pain in the ear, damage to the tympanic membrane;
• skin and subcutaneous tissues: treatment - dermatitis, including allergic and atopic;
• organ of vision: treatment - conjunctivitis, including eye pain, eye discharge, eye redness;
• blood and lymphatic system: treatment - lymphadenopathy.

Adverse reactions observed while taking the drug during post-marketing surveillance (the frequency of adverse effects and the causal relationship with the use of oseltamivir have not been established, since the true population size is unknown due to the voluntary nature of the reported messages):

• liver and biliary tract: increased activity of liver enzymes in persons with flu-like symptoms, taking the drug, jaundice, hepatitis, liver failure, fulminant hepatitis (including death);
• Gastrointestinal tract: gastrointestinal bleeding that occurs after taking the drug (the connection between the appearance of hemorrhagic colitis and the use of oseltamivir cannot be completely ruled out, since these phenomena took place both after the drug was discontinued and after the patient recovered);
• skin and subcutaneous tissues: hypersensitivity reactions, including skin rash, dermatitis, urticaria, eczema, Stevens-Johnson syndrome, erythema multiforme, toxic epidermal necrolysis, allergies, Quincke's edema, anaphylactic and anaphylactoid reactions;
• cardiovascular system: arrhythmia;
• organ of vision: visual impairment;
• neuropsychic sphere: abnormal behavior, hallucinations, delusions and other neurological symptoms and behavioral changes associated with influenza infection, in some cases with fatal outcome; these effects can develop both with the occurrence of encephalitis or encephalopathy, and without the appearance of these complications; when treating influenza with a drug, mainly in children and adolescents, convulsions and delirium were recorded, including nightmares, agitation, anxiety, delirium, hallucinations, disorientation in time and space, impaired consciousness, rarely occurring with life-threatening activity; with the development of these phenomena, the role of oseltamivir has not been determined, since such neuropsychiatric disorders were also recorded in patients with influenza who did not take oseltamivir.

Overdose

As a rule, in the course of clinical trials and during post-marketing use, an overdose of an antiviral agent did not cause any adverse reactions. In other cases, the signs of overdose were consistent with the above side effects.

special instructions

The threat of neuropsychiatric disorders in people taking oseltamivir does not exceed that in patients with influenza who do not use antiviral drugs. Careful monitoring of the condition and behavior of patients, especially children and adolescents, is necessary to identify signs of abnormal behavior and timely assess the risk of further use of the drug against the background of the development of these disorders.

The effectiveness of the drug for any lesions caused by pathogens other than influenza A and B viruses has not been established.

The antiviral agent Oseltamivir cannot be used as a substitute for vaccination.

Whenever possible, oseltamivir should be disposed of using special systems designed for drug processing. The drug should not be disposed of with household waste or sewage.

Influence on the ability to drive vehicles and complex mechanisms

The effect of the drug on the ability to drive a car and control other complex equipment has not been studied. However, given its safety profile, such an impact seems unlikely.

Application during pregnancy and lactation

Strictly controlled and adequate studies of the use of Oseltamivir during pregnancy have not been conducted. However, according to the results of observational and post-marketing studies, the benefits of the recommended standard dosing regimen for pregnant women have been noted. Pharmacokinetic analysis data showed a lower exposure (by about 30% throughout all trimesters of pregnancy) of the active metabolite in this group of patients. However, the calculated exposure was higher than inhibitory levels (IC ₉₅) and therapeutic values for a number of influenza strains. It is not recommended to change the dosage regimen in pregnant women during prophylaxis or treatment with the drug.

No direct or indirect negative effects of the drug on pregnancy, embryofetal or postnatal development were found in preclinical studies. When prescribing Oseltamivir during pregnancy, it is necessary to take into account the course of pregnancy, safety data, as well as the pathogenicity of the influenza virus strain circulating in this season.

During preclinical studies, it was found that oseltamivir and its active metabolite were excreted in the milk of lactating rats. According to limited data, the drug is also excreted in human breast milk and is found in the blood of an infant at subtherapeutic concentrations.

During pregnancy and lactation, the antiviral agent Oseltamivir should be used only if the expected benefit to the mother outweighs the possible threat to the fetus and baby.

Pediatric use

Oseltamivir is contraindicated in children under 1 year of age.

With impaired renal function

Patients with CC above 60 ml / min do not need to change the dose of Oseltamivir. With a CC of 30-60 ml / min, the dose of the drug should be reduced to 30 mg, the frequency of use for the purpose of therapy - 2 times a day for 5 days, for the purpose of prophylaxis - 1 time per day.

In patients with CC 10-30 ml / min, the drug is taken at a dose of 30 mg, the frequency of use for the purpose of therapy is 1 time per day for 5 days, for the purpose of prevention - 1 time per day every other day.

Persons on continuous hemodialysis are allowed to take the drug in the initial dose of 30 mg before dialysis (for the purpose of therapy - if signs of influenza occur within 48 hours between dialysis sessions). In order to maintain the plasma concentration of oseltamivir at a therapeutic level, the agent should be used at a dose of 30 mg, for therapy - after each dialysis session, for prophylaxis - after each odd session.

For persons on peritoneal dialysis, Oseltamivir should be used in an initial dose of 30 mg before dialysis, then 30 mg, for therapy - every 5 days, for prophylaxis - every 7 days.

Patients with renal failure in the terminal stage [with creatinine clearance (CC) of 10 ml / min and below] are contraindicated in taking the drug.

For violations of liver function

Oseltamivir dose adjustment is not required in patients with mild to moderate liver dysfunction.

The drug is contraindicated in patients with severe hepatic impairment.

Use in the elderly

Given the data on the exposure of the drug and its tolerability, dose adjustment is not required in the treatment and prevention of influenza in the elderly.

Drug interactions

Based on the data obtained from pharmacological and pharmacokinetic studies of the drug, clinically significant drug interactions are unlikely. The interactions of oseltamivir with drugs / agents associated with competition for binding to the active centers of esterases, with the participation of which oseltamivir phosphate is metabolized to TC, are not covered in detail in the literature.

Due to the low degree of binding of the prodrug and its active derivative to plasma proteins, it cannot be assumed that an interaction caused by the displacement of drugs from the binding to proteins is possible.

Possible drug interactions with other substances / preparations:

• probenecid: there is an increase in the AUC of the active metabolite by an average of 2 times as a result of a decrease in the active tubular secretion in the kidneys; dose changes are not required;
• cimetidine (a nonspecific blocker of isoenzymes of the cytochrome P _{450 system}): this substance in the process of tubular secretion is a competitor to alkaline agents and cations, does not affect the plasma concentrations of oseltamivir and OC;
• paracetamol: plasma concentrations of this substance, oseltamivir and its metabolite are not affected in any way;
• amoxicillin: no effect on the content of oseltamivir and its components in plasma was found, since there is little competition for excretion through anionic tubular secretion;
• methotrexate, chlorpropamide, butadione (drugs with a narrow range of therapeutic action): these combinations require special care;
• cimetidine, acetylsalicylic acid, paracetamol, antacids (calcium carbonate, aluminum and magnesium hydroxide), rimantadine, amantadine, warfarin: when used together, no pharmacokinetic interaction with oseltamivir or OC is detected;
• sympathomimetics (pseudoephedrine), β-blockers (propranolol), angiotensin converting enzyme (ACE) inhibitors (captopril, enalapril), blockers of H ₂ histamine receptor antagonists (cimetidine, ranitidine), antibiotics (doxycycline, azithromycin, penicillin, erythromycin, cephalosporins), xanthines (theophylline), thiazide diuretics (bendroflumethiazide), opiates (codeine), non-narcotic analgesics (ibuprofen, acetylsalicylic acid, paracetamol), inhaled bronchodilators, glucocorticosteroids: no changes in the frequency or severity of undesirable effects are recorded;
• oral contraceptives: there is no reason for interaction.

Analogs

Oseltamivir analogs are Nomides, Oseltamivir-Akrikhin, Influcein, Seltavir, Oseltamivir Avexima, Tamiflu, Oseltamivir-native, Flustop, etc.

Terms and conditions of storage

Store in a place protected from light, out of reach of children, at a temperature not exceeding 25 ° C.

Shelf life is 2 years.

Terms of dispensing from pharmacies

Dispensed by prescription.

Reviews of Oseltamivir

Currently, there are no reviews on Oseltamivir on medical sites, left by specialists or patients, by which it would be possible to realistically assess its effectiveness and disadvantages.

Oseltamivir price in pharmacies

There is no reliable data on the price of Oseltamivir, since the drug is currently not available in the pharmacy chain. The cost of an analogue of the drug - Oseltamivir Canon - can be 600-700 rubles. per package containing 10 capsules of 75 mg.

Oseltamivir: prices in online pharmacies

Drug name Price Pharmacy

Oseltamivir 75 mg capsule 10 pcs. 652 r Buy

Oseltamivir 75 mg capsule 10 pcs. RUB 699 Buy

Oseltamivir Avexima 75mg capsules 10 pcs. 859 r Buy

Oseltamivir caps. 75 mg 10 Pcs. RUB 950 Buy

Oseltamivir 75 mg capsule 30 pcs. 2141 RUB Buy

Maria Kulkes Medical journalist About the author

Education: First Moscow State Medical University named after I. M. Sechenov, specialty "General Medicine".

Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!